This system delivers CRISPR/Cas9 directly to tumor cells to knock down indoleamine 2,3-dioxygenase-1 (IDO1), a key immunosuppressive mediator often upregulated in aggressive cancers like triple-negative breast cancer. The gene discussed is IDO1; the disease is neoplasm.